ALX Oncology (ALXO) Stock Forecast, Price Target & Predictions
ALXO Stock Forecast
ALX Oncology stock forecast is as follows: an average price target of $24.50 (represents a 1231.52% upside from ALXO’s last price of $1.84) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ALXO Price Target
The average price target for ALX Oncology (ALXO) is $24.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $14.00. This represents a potential 1231.52% upside from ALXO's last price of $1.84.
ALXO Analyst Ratings
According to 5 Wall Street analysts, ALX Oncology's rating consensus is 'Buy'. The analyst rating breakdown for ALXO stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ALX Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 10, 2024 | Colin Bristow | UBS | $25.00 | $8.82 | 183.29% | 1258.70% |
| Jun 03, 2024 | Christopher Raymond | Raymond James | $21.00 | $9.10 | 130.77% | 1041.30% |
| Apr 10, 2024 | Bradley Canino | Stifel Nicolaus | $14.00 | $11.85 | 18.14% | 660.87% |
| Aug 09, 2022 | Credit Suisse | $38.00 | $11.77 | 222.85% | 1965.22% | |
| Jun 13, 2022 | Bradley Canino | Stifel Nicolaus | $16.00 | $6.79 | 135.81% | 769.57% |
The latest ALX Oncology stock forecast, released on Jun 10, 2024 by Colin Bristow from UBS, set a price target of $25.00, which represents a 183.29% increase from the stock price at the time of the forecast ($8.82), and a 1258.70% increase from ALXO last price ($1.84).
ALX Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $20.00 |
| Last Closing Price | $1.84 | $1.84 | $1.84 |
| Upside/Downside | -100.00% | -100.00% | 986.96% |
In the current month, the average price target of ALX Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ALX Oncology's last price of $1.84. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 10, 2024 | UBS | Buy | Buy | Hold |
| Jun 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 08, 2023 | Jefferies | Buy | Upgrade | |
| Aug 09, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| May 19, 2022 | Piper Sandler | Overweight | Overweight | Hold |
ALX Oncology's last stock rating was published by UBS on Jun 10, 2024. The company gave ALXO a "Buy" rating, the same as its previous rate.
ALX Oncology Financial Forecast
ALX Oncology Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.18 | - | $527.00K |
| Avg Forecast | - | - | - | - | - | - | - | $105.40K | $131.00K | $-36.40K | $250.00K | $550.00K |
| High Forecast | - | - | - | - | - | - | - | $105.40K | $131.00K | $-36.40K | $250.00K | $550.00K |
| Low Forecast | - | - | - | - | - | - | - | $105.40K | $131.00K | $-36.40K | $250.00K | $550.00K |
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.00% | - | 0.96% |
ALX Oncology's average Quarter revenue forecast for Mar 21 based on 1 analysts is $131.00K, with a low forecast of $131.00K, and a high forecast of $131.00K. ALXO's average Quarter revenue forecast represents a 11082810.32% increase compared to the company's last Quarter revenue of $1.18 (Dec 20).
ALX Oncology EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-16.27M | $-14.18M | $-18.44M | $-9.91M | $-11.01M |
| Avg Forecast | - | - | - | - | - | - | - | $21.08K | $-16.25M | $-7.28K | $50.00K | $-112.63M |
| High Forecast | - | - | - | - | - | - | - | $21.08K | $-13.00M | $-7.28K | $50.00K | $-90.11M |
| Low Forecast | - | - | - | - | - | - | - | $21.08K | $-19.50M | $-7.28K | $50.00K | $-135.16M |
| Surprise % | - | - | - | - | - | - | - | -771.62% | 0.87% | 2532.77% | -198.30% | 0.10% |
undefined analysts predict ALXO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ALX Oncology's previous annual EBITDA (undefined) of $NaN.
ALX Oncology Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-16.27M | $-14.19M | $-18.77M | $-10.18M | $-11.33M |
| Avg Forecast | $-34.15M | $-33.51M | $-34.36M | $-37.10M | $-35.30M | $-41.10M | $-38.79M | $-22.62M | $-16.26M | $-17.97M | $-17.93M | $-115.89M |
| High Forecast | $-34.15M | $-33.51M | $-34.36M | $-28.80M | $-29.59M | $-41.10M | $-38.79M | $-22.62M | $-13.01M | $-17.97M | $-17.93M | $-92.71M |
| Low Forecast | $-34.15M | $-33.51M | $-34.36M | $-45.39M | $-42.05M | $-41.10M | $-38.79M | $-22.62M | $-19.51M | $-17.97M | $-17.93M | $-139.06M |
| Surprise % | - | - | - | - | - | - | - | 0.72% | 0.87% | 1.04% | 0.57% | 0.10% |
ALX Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALXO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ALX Oncology SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $5.09M | $4.36M | $5.68M | $4.48M | $3.17M |
| Avg Forecast | - | - | - | - | - | - | - | $341.91K | $424.95K | $-118.08K | $810.98K | $1.78M |
| High Forecast | - | - | - | - | - | - | - | $341.91K | $424.95K | $-118.08K | $810.98K | $1.78M |
| Low Forecast | - | - | - | - | - | - | - | $341.91K | $424.95K | $-118.08K | $810.98K | $1.78M |
| Surprise % | - | - | - | - | - | - | - | 14.88% | 10.26% | -48.13% | 5.53% | 1.78% |
ALX Oncology's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ALXO last annual SG&A of $5.09M (Jun 21).
ALX Oncology EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.40 | $-0.35 | $-0.50 | $-0.36 | $-0.40 |
| Avg Forecast | $-0.65 | $-0.64 | $-0.65 | $-0.70 | $-0.67 | $-0.78 | $-0.75 | $-0.44 | $-0.41 | $-0.35 | $-0.35 | $-0.32 |
| High Forecast | $-0.65 | $-0.64 | $-0.65 | $-0.55 | $-0.56 | $-0.78 | $-0.75 | $-0.44 | $-0.41 | $-0.35 | $-0.35 | $-0.32 |
| Low Forecast | $-0.65 | $-0.64 | $-0.65 | $-0.86 | $-0.80 | $-0.78 | $-0.75 | $-0.44 | $-0.41 | $-0.35 | $-0.35 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | 0.92% | 0.85% | 1.44% | 1.04% | 1.26% |
According to undefined Wall Street analysts, ALX Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALXO previous annual EPS of $NaN (undefined).
ALX Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VIRX | Viracta Therapeutics | $0.22 | $8.00 | 3536.36% | Buy |
| ALXO | ALX Oncology | $1.79 | $24.50 | 1268.72% | Buy |
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| CABA | Cabaletta Bio | $2.75 | $16.33 | 493.82% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| BMEA | Biomea Fusion | $4.64 | $23.33 | 402.80% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| BCAB | BioAtla | $1.31 | $5.00 | 281.68% | Buy |
| IMTX | Immatics | $7.18 | $22.00 | 206.41% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| EYPT | EyePoint Pharmaceuticals | $8.02 | $22.00 | 174.31% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| DYN | Dyne Therapeutics | $26.16 | $49.00 | 87.31% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |